Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

A126 in the active site and TI167/168 in the TI loop are essential determinants of the substrate specificity of PTEN.

Leitner MG, Hobiger K, Mavrantoni A, Feuer A, Oberwinkler J, Oliver D, Halaszovich CR.

Cell Mol Life Sci. 2018 Nov;75(22):4235-4250. doi: 10.1007/s00018-018-2867-z. Epub 2018 Jul 9.

2.

Discovery and functional characterization of a neomorphic PTEN mutation.

Costa HA, Leitner MG, Sos ML, Mavrantoni A, Rychkova A, Johnson JR, Newton BW, Yee MC, De La Vega FM, Ford JM, Krogan NJ, Shokat KM, Oliver D, Halaszovich CR, Bustamante CD.

Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):13976-81. doi: 10.1073/pnas.1422504112. Epub 2015 Oct 26.

3.

A method to control phosphoinositides and to analyze PTEN function in living cells using voltage sensitive phosphatases.

Mavrantoni A, Thallmair V, Leitner MG, Schreiber DN, Oliver D, Halaszovich CR.

Front Pharmacol. 2015 Mar 31;6:68. doi: 10.3389/fphar.2015.00068. eCollection 2015.

4.

A human phospholipid phosphatase activated by a transmembrane control module.

Halaszovich CR, Leitner MG, Mavrantoni A, Le A, Frezza L, Feuer A, Schreiber DN, Villalba-Galea CA, Oliver D.

J Lipid Res. 2012 Nov;53(11):2266-74. doi: 10.1194/jlr.M026021. Epub 2012 Aug 15.

5.

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L.

J Virol. 2009 Jan;83(2):757-69. doi: 10.1128/JVI.02036-08. Epub 2008 Nov 5. Erratum in: J Virol. 2009 May;83(9):4713-5.

Supplemental Content

Loading ...
Support Center